CPC-111
Growth Hormone SecretagogueresearchAlso known as: Oral GH Secretagogue, CPC111
An experimental oral growth hormone secretagogue peptide designed to stimulate GH release through the ghrelin receptor, offering a potential alternative to injectable GH-releasing peptides.
Overview
CPC-111 is an investigational oral growth hormone secretagogue that acts on the ghrelin/GHS-R1a receptor pathway to stimulate pulsatile growth hormone release from the anterior pituitary. It belongs to a class of compounds being developed as oral alternatives to injectable GH secretagogues like GHRP-6 and ipamorelin. The appeal of CPC-111 lies in its oral bioavailability — most peptides are degraded in the GI tract, but CPC-111 has been designed with modifications to resist enzymatic breakdown. It is still in early-stage research and not widely available, but has generated interest in the biohacking community as a potential needle-free option for GH optimization. Limited published data exists, and users should approach with caution.
Mechanism of Action
CPC-111 binds to growth hormone secretagogue receptors (GHS-R1a), the same receptor targeted by ghrelin and MK-677. This triggers a signaling cascade in somatotroph cells of the anterior pituitary, resulting in pulsatile growth hormone release. Unlike exogenous GH, secretagogues maintain the body's natural feedback loops and pulsatile release pattern. The oral formulation uses structural modifications to resist pepsin and trypsin degradation in the GI tract, allowing sufficient bioavailability to achieve physiological GH elevation.
Molecular Formula
Not publicly disclosed
Molecular Weight
Not publicly disclosed
Sequence
Proprietary modified peptide
Dosage Protocols
Dose Range
100mcg – 500mcg
Frequency
Once daily
Route
oral
Cycle Length
8-12 weeks
Take on an empty stomach before bed or in the morning fasted. Dosing protocols are not well established — start low and titrate. Very limited clinical data available.
Source: Community protocols (limited)
🧮 Personalized Dosage Calculator
💰 Estimated Pricing
Typical Supply
5mg vial
Last Updated
2026-02
Experimental hair growth peptide. Very limited research availability. Early-stage compound.
⚠️ Prices are estimates based on publicly available data and may vary significantly by vendor, location, and prescription status. This is not medical or financial advice.
Side Effects
| Effect | Severity |
|---|---|
| Increased appetite | mild |
| Water retention | mild |
| Numbness/tingling | mild |
| Nausea | mild |
Pros & Cons
Oral administration eliminates the need for injections
Stimulates natural pulsatile GH release rather than flat exogenous levels
Potentially more convenient and accessible than injectable secretagogues
Very limited published research — efficacy and safety not well established
Actual oral bioavailability is uncertain and may vary significantly
Not widely available and quality/purity hard to verify
May increase appetite similar to other ghrelin-pathway secretagogues
🩸 Blood Work
No specific bloodwork requirements reported for this peptide. General health panels are always recommended before starting any peptide protocol.
Legal Status
Investigational compound. Not FDA-approved. Available from select research chemical suppliers. Limited regulatory classification.
Readers Also Viewed
Semaglutide
99An FDA-approved GLP-1 receptor agonist used for type 2 diabetes and chronic weight management, producing significant weight loss of 15-17% body weight in clinical trials.
BPC-157
98A 15-amino acid synthetic peptide derived from human gastric juice that promotes healing of tendons, ligaments, muscles, gut lining, and other tissues through multiple regenerative pathways.
Tirzepatide
97A first-in-class dual GIP/GLP-1 receptor agonist that produces up to 22.5% body weight loss, approved for type 2 diabetes and obesity management.
CJC-1295 + Ipamorelin (Combo)
95The most popular growth hormone peptide combination, pairing a GHRH analog (CJC-1295) with a ghrelin mimetic (Ipamorelin) for synergistic GH release with minimal side effects.
Related Peptides
Semaglutide
An FDA-approved GLP-1 receptor agonist used for type 2 diabetes and chronic weight management, producing significant weight loss of 15-17% body weight in clinical trials.
Tirzepatide
A first-in-class dual GIP/GLP-1 receptor agonist that produces up to 22.5% body weight loss, approved for type 2 diabetes and obesity management.
CJC-1295 + Ipamorelin (Combo)
The most popular growth hormone peptide combination, pairing a GHRH analog (CJC-1295) with a ghrelin mimetic (Ipamorelin) for synergistic GH release with minimal side effects.
Collagen Peptides
Bioactive peptide fragments derived from hydrolyzed collagen protein that support skin elasticity, joint health, bone density, hair/nail growth, and gut lining integrity through stimulation of endogenous collagen synthesis.